Along this line, we have previously shown that the functional targeting of bone marrow‐derived monocytes using a mutant, signal‐transduction incompetent VEGFR‐1 significantly slows tumor growth in the same GL261 glioma model as applied in the current study (Kerber et al, 2008). Here, FLT1 is linked to glioma.